

1 **Harnessing Photoenzymatic Reactions for Unnatural Biosynthesis in Microorganisms**

2 Yujie Yuan^{1,2,3†}, Maolin Li^{1,2,3†,#}, Wesley Harrison^{1,2,3}, Zhengyi Zhang^{1,2,3}, Huimin Zhao^{1,2,3,4,5*}

3 ¹DOE Center for Advanced Bioenergy and Bioproducts Innovation, University of Illinois Urbana-
4 Champaign; Urbana, IL 61801, USA. ²Department of Chemical and Biomolecular Engineering,
5 University of Illinois Urbana-Champaign; Urbana, IL 61801, USA. ³Carl Woese Institute for Genomic
6 Biology, University of Illinois Urbana-Champaign; Urbana, IL 61801, USA. ⁴NSF Molecular Maker
7 Lab Institute, University of Illinois Urbana-Champaign; Urbana, IL 61801, USA. ⁵NSF iBioFoundry,
8 University of Illinois Urbana-Champaign; Urbana, IL 61801, USA.

9 †These authors contributed equally to this work.

10 #Present address: Frontier Science Center for the Creation of New Organic Substances, Nankai
11 University, Tianjin, 300350, China

12 *Correspondence to: zhao5@illinois.edu


13 **Abstract:** Photobiocatalysis provides a powerful strategy for integrating light and biological catalysts
14 to drive abiological transformations. However, its scalability is hindered by high enzyme loading,
15 reliance on costly cofactors, and instability under radical-generating conditions. Here we report the
16 integration of light-driven enzymatic reactions into the cellular metabolism of *Escherichia coli*,
17 bridging flavin-based photobiocatalysis with biosynthesis. Using synthetic biology strategies, we
18 engineered microbial cells to continuously produce olefin substrates and ene-reductase while
19 regenerating cofactors directly from glucose. By externally supplying radical precursors or by
20 introducing synthetic pathways for their *in situ* production, we enabled fermentation-based microbial
21 photobiosynthesis, achieving high titres and demonstrating its feasibility for scale-up in bioreactor. This
22 approach extends photobiocatalysis from *in vitro* applications to *in vivo* semi and complete biosynthesis,
23 revealing its full potential for integrating light-driven reactions into cellular metabolism.

24 **Main Text:** Biosynthesis enables the precise assembly of complex molecules but remains limited by
25 nature's enzymatic repertoire. Integrating new-to-nature reactivity into living systems offers a powerful
26 means to expand chemical space and enable the rational design of non-natural products¹⁻⁹.
27 Photoenzymatic catalysis, which couples enzymatic selectivity with light-driven radical intermediates,
28 provides a transformative route to such reactivity, supporting a range of new biotransformations
29 including amino acid synthesis, multicomponent couplings, and cycloadditions^{3,10,11}. These
30 transformations leverage both natural and synthetic photoactive elements, such as flavin cofactors,
31 chemical photocatalysts, and photoactive non-canonical amino acids (**Fig. 1a**)^{3,11-21}. Despite this
32 promise, current photoenzymatic platforms face major limitations in scalability due to high enzyme
33 loading (e.g., 2-4 g enzyme/L reaction volume), poor stability, and the need for protein purification.
34 Most prior efforts have focused on expanding reactivity *in vitro* or in whole-cell systems, without
35 addressing their translation to robust and scalable production^{3,8,11,21-23}. Overcoming these constraints is
36 essential for realizing the potential of photoenzymatic catalysis in synthetic biology and industrial
37 biotechnology.

38 Synthetic biology provides a powerful framework for designing and engineering biological
39 systems, enabling the construction of improved and novel enzymes, genetic circuits, and microbial cell
40 factories²⁴. This approach has been instrumental in the sustainable production of high-value natural
41 products such as artemisinin²⁵, cannabinoids²⁶, vinblastine^{27,28}, and vaccine adjuvant QS-21²⁹. To
42 extend biosynthesis beyond natural reactivity, an effective strategy involves integrating *in vitro* new-to-
43 nature enzymatic reactions into *in vivo* biosynthetic pathways, enabling the efficient production of

44 unnatural high-value compounds. A notable example is the microbial platform recently developed by
 45 the Hartwig and Keasling groups, which successfully incorporated unnatural carbene-transfer reactions
 46 into biosynthesis^{30,31}.

47 Inspired by these advances, here we developed an *in vivo* photobiosynthesis platform by
 48 integrating photoenzymatic reactions into living systems, enabling scalable and sustainable
 49 photoreactions in microbial organisms. Specifically, we engineered *E. coli* to facilitate photoinduced
 50 hydroalkylation, hydroamination, and hydrosulfonylation for diverse unnatural product biosynthesis by
 51 co-expressing an ene-reductase photoenzyme with a *de novo* designed olefin biosynthetic pathway and
 52 supplementing a radical precursor. Additionally, we incorporated an indole biosynthetic pathway and
 53 applied directed evolution to enhance the hydroarylation activity with 4-vinylphenol under blue light,
 54 culminating in the complete *de novo* biosynthesis of phenol-indole analogue (DIEP) (**Fig. 1b**). The
 55 intracellular environment provides a renewable catalytic system, ensuring sustained enzymatic activity
 56 for efficient, light-driven biosynthesis.



57
 58 **Fig. 1. Integration of *in vitro* new-to-nature enzymatic reactions into *in vivo* biosynthetic pathways.**
 59 **a**, Existing strategies for developing *in vitro* photobiocatalytic reactions include: a) utilizing
 60 photoenzymes containing natural photoactive cofactors; b) coupling enzymes with chemical
 61 photocatalysts; c) designing artificial photoenzymes. **b**, Overview of an *in vivo* photobiosynthesis
 62 platform that integrates new-to-nature photoenzymatic reactions into the cellular metabolism of *E. coli*.
 63 FMN, flavin mononucleotide; FAD, flavin adenine dinucleotide; NADP⁺, nicotinamide adenine
 64 dinucleotide phosphate; bpy, 2,2'-bipyridyl; ppy, 2-phenylpyridine; DIEP, 4-(2-(3a,7a-dihydro-1H-
 65 indol-3-yl)ethyl)phenol.


66 Results

67 Design and optimization of an *in vivo* photobiosynthesis platform

68 FMN-dependent ene-reductases exhibit broad substrate promiscuity with diverse radical precursors
69 *in vitro* and have recently been shown to incorporate fluorinated motifs into olefins, addressing the
70 scarcity of natural enzymes capable of synthesizing fluorinated compounds in living organisms^{32,33}.
71 Inspired by this, we envisioned integrating photoenzymatic fluorine utilization into microbial
72 biosynthetic pathways, establishing an *in vivo* photobiosynthesis platform to enable microbial
73 production of fluorinated compounds. We selected trifluoroiodoethane (TFIE) as an effective fluorine
74 donor and 4-vinylphenol, a radical acceptor that can be produced in engineered microorganisms. Initial
75 *in vitro* screenings with ene-reductases and their mutants under blue light identified the variant of old
76 yellow enzyme 3 (OYE3_N194Y) as a highly active catalyst, achieving a ~50% yield (**Supplementary**
77 **Table 1**). We then reconstituted the biosynthetic pathway for 4-vinylphenol in *E. coli* BL21(DE3) by
78 overexpressing the required genes (*palY*, *padA*), along with tyrosine biosynthesis-enhancing genes (*tktA*,
79 *aroF*, *ppsA*, *tyrA*) to enable glucose-to-4-vinylphenol conversion³⁴ (**Supplementary Figs. 1 and 2**).
80 Under flask fermentation conditions, the engineered photobiosynthesis strain 1 (PBS1) achieved a 4-
81 vinylphenol titre of 129 mg L⁻¹ after 48 h in Luria-Bertani (LB) medium. Next, we incorporated the
82 photoenzyme (OYE3_N194Y) expression pathway into the *E. coli* strains harboring the 4-vinylphenol
83 producing pathway (**Figs. 2a and 2b**). For the initial investigation, we developed PBS6, expressing
84 only the photoenzyme and substrate synthesis pathways. Under blue-light irradiation and in an oxygen-
85 free environment, fermentation with TFIE resulted in a 4-(4,4,4-trifluorobutyl) phenol (TFBP) product
86 titre of 2.14 mg L⁻¹. In contrast, no TFBP production was observed in the control strain PBS4, which
87 lacks substrate production, and low TFBP production (0.97 mg L⁻¹) was detected in PBS5 without
88 photoenzyme overexpression, which may be attributed to endogenous background enzymes in *E. coli*
89 BL21(DE3) that exhibit weak catalytic activity (**Fig. 2c, Supplementary Fig. 3**).

90 NADPH serves as the key cofactor for FMNH regeneration in enzymatic hydroalkylation. To
91 enhance cellular NADPH levels, a set of endogenous (glucose-6-phosphate dehydrogenase, ZWF;
92 membrane-bound transhydrogenase, PntAB; soluble transhydrogenase, UdhA; isocitrate
93 dehydrogenase, ICD) and heterologous (glucose dehydrogenase, GDH; NADH kinase, Pos5; NADP-
94 dependent glyceraldehyde-3-phosphate dehydrogenase, GapC; phosphite dehydrogenase, PTDH;
95 formate dehydrogenases, FDH) NADPH-generating enzymes previously reported were targeted for
96 overexpression³⁵. We found that GDH overexpression (in PBS7) and ICD overexpression (in PBS8)
97 improved the TFBP titre by 2.73-fold (7.93 mg L⁻¹ vs. 2.14 mg L⁻¹) and 1.41-fold (5.15 mg L⁻¹ vs. 2.14
98 mg L⁻¹), respectively (**Supplementary Figs. 4a-4c**). Additionally, we evaluated the effect of co-
99 expressing GDH and ICD. However, the TFBP titres in the co-expression strains PBS16 and PBS17
100 were lower than those observed in strains expressing GDH (PBS7) or ICD (PBS8) individually (7.93
101 mg L⁻¹ vs. 5.74 mg L⁻¹; 5.15 mg L⁻¹ vs. 3.92 mg L⁻¹, respectively). Further optimization of photoenzyme
102 and NADPH-generating enzyme expression was achieved by regulating the promoter strength.
103 Compared to constructs utilizing strong promoters T7, a combination of the Trc promoter (strong) for
104 the photoenzyme and the Lac promoter (weak) for NADPH generation resulted in a notable
105 improvement in TFBP production (13.78 mg L⁻¹ vs. 7.93 mg L⁻¹ for GDH and 11.41 mg L⁻¹ vs. 5.15 mg
106 L⁻¹ for ICD) in PBS24 and PBS25, respectively (**Supplementary Fig. 4d**). To evaluate the effect of
107 radical precursor availability, TFIE concentrations were varied from 1 mM to 40 mM, with an optimal
108 TFBP titre observed at 10 mM both in PBS24 and PBS25 (**Supplementary Fig. 5**). We further evaluated

109 substrate supply and photoenzyme production by adjusting the plasmid origin of replication to regulate
 110 gene copy numbers³⁶. TFBP production was significantly improved compared to the initial strain (PBS6)
 111 (41.41 mg L⁻¹ vs. 2.14 mg L⁻¹ and 35.44 mg L⁻¹ vs. 2.14 mg L⁻¹) when a medium-copy plasmid (pBR322
 112 ori, ~40 copies) was used for substrate production and a high-copy plasmid (pRSF ori, >100 copies)
 113 was employed for photoenzyme production in PBS28 and PBS29, respectively (**Fig. 2c**,
 114 **Supplementary Fig. 4e**). Additionally, a comparative analysis was conducted to evaluate the catalytic
 115 efficiency between strains co-expressing the substrate pathway and photoenzyme, and those expressing
 116 only the photoenzyme with exogenous supplementation of 4-vinylphenol. The results showed that
 117 TFBP titres were significantly lower in these strains lacking substrate production (17.24 mg L⁻¹ in
 118 PBS30 and 15.66 mg L⁻¹ in PBS31) despite exogenous 4-vinylphenol addition, likely due to limited
 119 membrane permeability. In contrast, intracellular biosynthesis ensures continuous and localized
 120 substrate availability near the photoenzyme, thereby enhancing catalytic efficiency (**Supplementary**
 121 **Fig. 4f**).



122
 123 **Fig. 2. Design and optimization of an *in vivo* photobiosynthesis platform.** **a**, Design of a
 124 photobiosynthetic microbial cell by integrating olefin substrate biosynthetic enzymes (orange),
 125 photoenzyme (yellow), and NADPH-generating enzymes (GDH and ICD). Dotted arrows represent
 126 multistep catalytic processes. **b**, Construction of photobiosynthesis strains. p-Substrate contains
 127 substrate (4-vinylphenol) biosynthetic enzymes. p-Photoenzyme contains photoenzyme and GDH or
 128 ICD. **c**, Optimization of photobiosynthesis platform, including the evaluation of NADPH-enhancing


129 systems for photobiosynthesis in microorganisms, combinatorial optimization of promoters for the
130 overexpression of photoenzyme and GDH or ICD, and balancing substrate supply and photoenzyme
131 production by adjusting plasmid origin of replication. OYE3, old yellow enzyme 3 from *Saccharomyces*
132 *cerevisiae*; Single-letter abbreviations for the amino acid residues: N-Asn (Asparagine), Y-Tyr
133 (Tyrosine); GDH, glucose dehydrogenase; ICD, isocitrate dehydrogenase; TktA, transketolase; AroF,
134 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthetase; PpsA, phosphoenolpyruvate
135 synthase; TyrA, tyrosine synthase; PALY, phenylalanine ammonia lyase from *Rhodotorula toruloides*;
136 PadA, decarboxylase from *Lactiplantibacillus plantarum*; F6P, fructose 6-phosphate; GAP,
137 glyceraldehyde 3-phosphate; PEP, phosphoenolpyruvate; PYR, pyruvate; CIT, citrate; ICIT, isocitrate;
138 X5P, xylulose 5-phosphate; E4P, erythrose 4-phosphate; CHO, chorismate; PPA, prephenate; HPP, 4-
139 hydroxyphenylacetone; pHCA, *p*-hydroxy-cinnamic acid; TFIE, trifluoroiodoethane; TFBP, 4-(4,4,4-
140 trifluorobutyl)phenol; RBS, ribosome binding site; P_{T7}, T7 promoter; P_{trc}, trc promoter; P_{lac}, lac
141 promoter; T_{T7}, T7 terminator; T_{λ0}, λ0 terminator; ori, origin of replication; TCA, tricarboxylic acid; PBS,
142 photobiosynthesis strain. The data represent three independent experiments and are presented as the
143 mean ± s.d.

144 **Expanding the scope to various photoenzymatic reactions**

145 To broaden the applicability of the *in vivo* photobiosynthesis platform, various photoenzymatic
146 transformations were explored. For an additional olefin substrate, we reconstituted a styrene
147 biosynthetic pathway in *E. coli* by overexpressing the required genes (*pal2* and *fdc1*) along with the
148 precursor (phenylalanine) biosynthetic genes (*tktA*, *ppsA*, *aroF*, and *pheA*)³⁷ (**Supplementary Figs. 6**
149 **and 7**). Under flask fermentation conditions, the engineered strain (PBS32) produced 75.17 mg L⁻¹ of
150 styrene after 72 h in LB medium. The most efficient photobiosynthesis platform was then evaluated for
151 its compatibility with various enzymatic hydroalkylation^{12,38-41}, hydroamination⁴², and
152 hydrosulfonylation⁴¹ reactions (**Fig. 3a**). The biologically synthesized styrene or 4-vinylphenol
153 underwent radical-mediated transformations with different precursors, including piperidin-1-yl
154 benzoate, 2-bromo-1-phenylethanone, 4-methylbenzene-1-sulfonyl chloride, 4-(bromomethyl)pyridine,
155 and 2,2-dichloro-1-(pyrrolidin-1-yl)ethanone, yielding unnatural products with titres ranging from 4.5
156 mg L⁻¹ to 98.3 mg L⁻¹ (**Figs. 3b-3f, Supplementary Figs. 8-12**). The photobiosynthetic cells
157 demonstrated high compatibility with the azaarene-type photoenzymatic radical reaction, achieving a
158 titre of 98.3 mg L⁻¹ (**Fig. 3e**). Furthermore, the results revealed comparable enantioselectivities of the
159 asymmetric photoenzymatic reaction for α -chloroamide synthesis both *in vivo* and *in vitro* (86% vs. 91%
160 *ee*) (**Fig. 3f, Supplementary Fig. 13**). The reduced stereo-selectivity may be attributed to endogenous
161 enzymes in *E. coli* catalyzing the reaction with minimal catalytic activity (**Supplementary Fig. 14**).

162 We next aimed to explore the feasibility of scaling up highly challenging photoenzymatic reactions,
163 including those requiring precise light sources and strict anaerobic conditions, using a microbial
164 platform. To this end, we initially conducted photobiosynthetic fermentation in microbioreactors.
165 Compared with whole-cell catalysis using resting cells—particularly regarding cell recycling efficiency
166 and sustained cofactor turnover, a key advantage of fermentation systems lies in the metabolically active
167 state of cells, which enables continuous endogenous cofactor regeneration, enzyme production, and
168 substrate replenishment through engineered metabolic pathways. In flavin-dependent photoenzymatic
169 catalysis, the exclusion of oxygen is critical due to its dual inhibitory roles: molecular oxygen rapidly
170 quenches alkyl radical intermediates, thereby suppressing productive coupling; and under light
171 irradiation, oxygen oxidizes the reduced FMN cofactor (FMNH⁻), depleting the system's reductive

172 capacity and hindering radical generation via single-electron transfer. These effects severely limit
173 catalytic efficiency. To maintain both radical stability and enzymatic activity, photobiosynthesis must
174 therefore proceed under strictly anaerobic conditions. Therefore, a dual-phase fed-batch fermentation
175 process was implemented: Phase I involved substrate production under aerobic conditions, while Phase
176 II initiated photobiosynthesis under blue light in a nitrogen environment. Utilizing this strategy, we
177 evaluated the scale-up of representative photoenzymatic reactions to produce fluorinated-, azaarene-,
178 and α -chloroamide-based unnatural products (TFBP, PPPy, CPPB) through glucose feeding. Monitoring
179 the fermentation process revealed improvements in product titres: TFBP was increased by 1.56-fold
180 (64.65 mg L^{-1}), PPPy by 1.76-fold (172.04 mg L^{-1}), and CPPB by 3.46-fold (38.03 mg L^{-1}) (**Fig. 3g,**
181 **Supplementary Fig. 15**). These results demonstrated the potential for scaling up photoenzymatic
182 reactions under automated and precise control of conditions such as dissolved oxygen (DO), nitrogen
183 flow, and agitation in bioreactors.



184
185
186
187
188
189
190
191
192

Fig. 3. Expanding the scope of the *in vivo* photobiosynthesis platform. **a**, Schematic of a general strategy for photobiosynthesis with a diverse range of photoenzymatic reactions. **b-f**, Incorporation of photoenzymatic reactions triggered by radical precursors, including piperidin-1-yl benzoate, 2-bromo-1-phenylethanone, 4-methylbenzene-1-sulfonyl chloride, 4-(bromomethyl)pyridine, and 2,2-dichloro-1-(pyrrolidin-1-yl)ethanone, within microbial cells. **g**, Evaluation of the scalability of photoenzymatic reactions in the microbial platform through bioreactor fermentation. The data represent three independent experiments and are presented as the mean \pm s.d. FG, function group; LG, leaving group; PEP, 4-(2-(piperidin-1-yl)ethyl)phenol; DIPPB, 1,4-diphenylbutan-1-one; MPSB, 1-methyl-4-

193 (phenethylsulfonyl)benzene; PPPy, 4-(3-phenylpropyl) pyridine; CPPB, 2-chloro-4-phenyl-1-
194 (pyrrolidin-1-yl)butan-1-one; IPTG, isopropyl- β -D-thiogalactoside; OYE3, old yellow enzyme 3 from
195 *S. cerevisiae*; OYE1, old yellow enzyme 1 from *S. patorianus*; GluER, the ene-reductase from
196 *Gluconobacter oxydans*. OYE3_N194Y, OYE1, OYE1_Y82F, OYE1_H191A, and GluER_M6 were
197 the optimal photoenzymes used for the corresponding reactions. *pal*: *paly* for 4-vinylphenol production
198 and *pal2* for styrene production; *pad*: *padA* for 4-vinylphenol production and *fdc* for styrene production.
199 *The enantioselective excess (*ee*) value was determined by isolating products from *E. coli* fermentation
200 broth using chiral gas chromatography (GC).

201 Complete integration of a photoenzymatic reaction into cellular metabolism

202 Building on the successful incorporation of photoenzymatic reactions into microbial cells via
203 radical precursor feeding, we sought to achieve complete pathway integration by reconstituting the
204 biosynthetic pathways for the radical precursor, substrate, and photoenzyme in *E. coli*. Indole is a
205 structural motif frequently found in pharmaceutically active molecules, contributing to diverse
206 biological activities⁴³. Inspired by a recent work on redox-neutral radical hydroarylation⁴⁴, a model
207 photoenzymatic route was designed, wherein indole couples with 4-vinylphenol, catalyzed by a
208 photoenzyme in microbial cells, thereby expanding the biosynthetic strategy for indole-derived
209 compounds. In *E. coli*, indole biosynthesis occurs via tryptophanase, which reversibly converts
210 tryptophan into indole, pyruvate, and ammonia within the tryptophan metabolic pathway⁴⁵
211 (**Supplementary Figs. 16 and 17**). By encoding the *tnaA* gene in *E. coli* strains, indole production was
212 achieved with a titre of 57.13 mg L⁻¹ in PBS41 under flask condition. To construct the initial complete
213 photobiosynthesis strain, *tnaA* was co-overexpressed with the 4-vinylphenol and OYE1 biosynthetic
214 pathways (**Fig. 4a and 4b**). The strain (PBS42) was cultivated under blue light irradiation in an oxygen-
215 free environment, enabling the complete biosynthesis of unnatural product DIEP. After 48 h of
216 fermentation in LB medium, DIEP was detected, achieving a titre of 0.71 mg L⁻¹ (**Fig. 4c**).





217 Previous mechanistic investigations revealed that the free cofactor riboflavin 5-monophosphate
218 sodium salt (FMN-Na) enhanced the yield of photoinduced hydroarylation *in vitro*⁴⁴. A concentration-
219 dependent analysis showed that increasing FMN-Na to 1 mM significantly improved DIEP production
220 (5.42 mg L⁻¹), while concentrations exceeding 1 mM provided no further enhancement (**Fig. 4c**,
221 **Supplementary Fig. 18**). To further optimize enzyme expression levels, plasmid origins of replication
222 were adjusted. DIEP production was increased in strain PBS43 when a high-copy plasmid (pRSF
223 ori, >100 copies) was used for photoenzyme expression, compared to strain PBS42, which utilized a
224 medium-copy plasmid (pBR322 ori, ~40) (17.82 mg L⁻¹ vs. 5.42 mg L⁻¹). In both strains, the 4-
225 vinylphenol biosynthetic pathway was maintained on medium-copy plasmids, while the indole
226 biosynthetic enzyme was encoded on low-copy plasmids to optimize metabolic flux and minimize
227 cellular burden (**Fig. 4c**). To further enhance titres, protein engineering was applied to improve the
228 activity of the photoenzyme old yellow enzyme 1 (OYE1) for indole and 4-vinylphenol *in vivo*. A
229 mutant library comprised of 95 OYE1 variants with substitutions near the active site was generated and
230 screened using a high-throughput whole-cell based screening protocol. The workflow involved parallel
231 cultivation, reaction, and product analysis in multi-well plates. After protein expression in 24-deep-well
232 plates, concentrated cells were transferred to 96-deep-well plates for photobiocatalytic reactions under
233 anaerobic illumination. Products were extracted post-reaction and analyzed by LC-MS, enabling rapid
234 screening of engineered variants. After three rounds of targeted mutagenesis and one round of gene

235 recombination by the staggered extension process (StEP)⁴⁶, we obtained an OYE1 variant
236 Y82G/T37Q/W116A/H191S with the highest catalytic efficiency in whole-cell photoenzymatic
237 reactions, demonstrating a 12.7-fold activity improvement compared to wild type OYE1 (OYE1_WT)
238 (**Supplementary Table 6**). Subsequently, photobiosynthetic strains expressing OYE1 variants (Y82G
239 in PBS44, Y82G/T37Q in PBS45, and Y82G/T37Q/W116A/H191S in PBS46) were constructed and
240 cultured under blue-light fermentation, where the observed titres aligned with whole-cell based
241 screening results (**Supplementary Fig. 20**). The PBS46 strain, harboring the
242 Y82G/T37Q/W116A/H191S variant, achieved a high titre of 94.06 mg L⁻¹, representing a 4.28-fold
243 improvement compared to OYE1_WT (17.82 mg L⁻¹) (**Fig. 4c**).

244 To further enhance fermentation yields, fed-batch fermentation in a bioreactor was conducted,
245 providing better O₂ availability and pH control. The best-performing strain (PBS46) was evaluated for
246 DIEP production using glucose as the carbon source, demonstrating further optimization of microbial
247 photobiosynthesis under controlled conditions. To characterize product formation dynamics, a dual-
248 phase fermentation profile was established, comprising three distinct stages: Stage 1: The strain was
249 cultured under O₂ until the substrate accumulation reached its target peak, after which O₂ was replaced
250 with N₂; Stage 2: N₂ was maintained for approximately 10 hours without blue light to deplete residual
251 O₂ in the medium and cells; Stage 3: Photobiosynthesis was initiated with the introduction of blue
252 light (**Supplementary Fig. 21a**). Throughout the process, product formation, glucose and substrate
253 consumption and accumulation, and cell growth were monitored. After the substrate reached its peak
254 accumulation and O₂ was depleted, photobiosynthesis was initiated, leading to the production of 0.34 g
255 L⁻¹ DIEP at 191 h (**Supplementary Figs. 21b and 22a**). Next, we assessed the optimal ratio of indole
256 to 4-vinylphenol under fermentation conditions. The results showed that the highest yield was achieved
257 when the substrate ratio ranged from 1:1 to 1:2 (**Supplementary Fig. 23**). Based on this finding, we
258 optimized the timing of light exposure initiation at substrate accumulations within this ratio to maintain
259 maximum enzyme catalytic activity, achieving a product titre of 0.36 g L⁻¹ (**Supplementary Fig. 21c**
260 **and 22b**). Throughout the fermentation process, indole production was suppressed as 4-vinylphenol
261 accumulated, likely attributed to the competitive inhibition from the shared amino acid precursor, the
262 same expression regulation system induced by IPTG, and the biotoxicity of 4-vinylphenol toward *E.*
263 *coli* BL21(DE3), inhibiting the physiological metabolism of the strain and reducing synthesis
264 efficiency⁴⁷. To overcome the constraints, we implemented two separate sequential induction systems,
265 with arabinose initiating indole production at the initial stage, followed by IPTG induction for 4-
266 vinylphenol and photoenzyme expression. The results revealed that the production of DIEP was
267 significantly improved, reaching a titre of 0.62 g L⁻¹, a 33.79-fold improvement compared to the parent
268 strain PBS43 (17.82 mg L⁻¹) (**Fig. 4d and Supplementary Fig. 22c**). We also evaluated DIEP
269 production in M9 minimal medium. Although the titre (0.2 g L⁻¹) was lower than in LB rich medium,
270 it still represented a 280.69-fold improvement compared to the parent strain, demonstrating scalability
271 in bioreactor conditions. In addition, we investigated the effect of varying light intensity (25%, 50%,
272 75%, and 100%) on DIEP production. The results showed that higher light intensities led to increased
273 titres, suggesting that light diffusion within the bioreactor is a key factor and that sufficient illumination
274 is essential for high production (**Supplementary Fig. 24**). Furthermore, live/dead staining analysis
275 revealed a decrease in cell viability during the photoreaction, with live cell ratios ranging from 60% to
276 80%. These findings suggest that prolonged exposure to photoreaction conditions can lead to partial
277 cell damage, which may negatively affect product generation (**Supplementary Fig. 25**).

278 In addition, the bioactivity evaluation of DIEP revealed its broad-spectrum antimicrobial activity

279 against gram-negative and gram-positive bacteria, including the multidrug-resistant pathogens such as
280 Methicillin-resistant *Staphylococcus aureus* (MRSA), vancomycin-resistant *Enterococcus faecium*
281 U503 (VRE) and *Acinetobacter baumannii*, as well as fungi, with low minimum inhibitory
282 concentration (MIC) values ranging from 16 to 32 $\mu\text{g mL}^{-1}$ (**Fig. 4e, Supplementary Figs. 26 and 27**).
283 Notably, DIEP also exhibited antibacterial activity against *E. coli*, and as demonstrated in our
284 antimicrobial assays (**Supplementary Fig. 28**), cell growth was significantly inhibited when the
285 concentration exceeded 0.5 g L⁻¹. Therefore, the accumulation of DIEP during fermentation could
286 potentially inhibit cell growth and limit its production titre.



287

288 **Fig. 4. Coupling photoenzymatic reaction into metabolic networks.** **a**, Schematic of engineering a
 289 photobiosynthetic strain with the substrates and enzymes made by the cells. Dotted arrows represent
 290 multistep catalytic processes. **b**, Construction of complete photobiosynthesis strains. **c**, Optimization of
 291 DIEP production by regulating FMN-Na supply and gene copy numbers and applying protein
 292 engineering. Strain PBS42 used a medium-copy plasmid (pBR322 ori, ~40 copies) for photoenzyme

293 expression, while PBS43-PBS46 employed a high-copy plasmid (pRSF ori, >100 copies). Both strains
294 maintained the 4-vinylphenol pathway on medium-copy plasmids and indole biosynthetic enzymes on
295 low-copy plasmids (p15A ori, ~10 copies). Modeled structure of OYE1 was conducted using AutoDock
296 Vina⁴⁸. **d**, DIEP production from glucose in bioreactor fermentation. The data presented corresponds to
297 the anaerobic phase under blue light. **e**, Bioactivity evaluation of DIEP. Data of **d** are presented as
298 mean \pm s.d. of biological duplicates ($n = 2$), and data of **c** and **e** are presented as mean \pm s.d. of biological
299 triplicates ($n = 3$). DIEP, 4-(2-(3a,7a-dihydro-1H-indol-3-yl)ethyl)phenol; FMN-Na, riboflavin 5-
300 monophosphate sodium salt; OYE1, old yellow enzyme 1 from *S. patorianus*; TktA, transketolase; AroF,
301 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) synthetase; PpsA, phosphoenolpyruvate
302 synthase; TyrA, tyrosine synthase; PALY, phenylalanine ammonia lyase from *Rhodotorula toruloides*;
303 PadA, decarboxylase from *Lactiplantibacillus plantarum*; F6P, fructose 6-phosphate; PEP,
304 phosphoenolpyruvate; PYR, pyruvate; E4P, erythrose 4-phosphate; CHO, chorismate; PPA, prephenate;
305 HPP, 4-hydroxyphenylacetone; pHCA, *p*-hydroxy-cinnamic acid; Tyr, tyrosine; Trp, tryptophan; TnaA,
306 tryptophanase. Single-letter abbreviations for the amino acid residues: Y, Tyr; G, Gly; T, Thr; Q, Gln;
307 W, Trp; A, Ala; H, His; S, Ser.

308 **Conclusions**

309 This study demonstrates the successful integration of photoenzymatic catalysis into microbial
310 biosynthesis, establishing a scalable *in vivo* photobiosynthetic platform that enables light-driven
311 enzymatic transformations in living cells. By incorporating FMN-dependent ene-reductases into
312 engineered *E. coli*, this system facilitates the semi-biosynthesis of diverse unnatural products and
313 achieves *de novo* complete biosynthesis of DIEP through simultaneous expression of photoenzyme as
314 well as reconstitution of radical precursor and substrate biosynthetic pathways within microbial
315 organisms. This work establishes a rational and programmable framework for microbial
316 photobiosynthesis, expanding the synthetic capabilities of biological systems beyond nature's
317 constraints. These findings have laid the foundation for sustainable biomanufacturing, offering
318 opportunities for production of high-value pharmaceuticals, bioactive molecules, and complex natural
319 products through light-driven enzymatic transformations in living systems.

320 **Methods**

321 **Materials and reagents.** Polymerase chain reaction (PCR) amplification of DNA fragments for
322 plasmid construction was performed using PrimeSTAR[®] Max DNA Polymerase (R045B, TaKaRa,
323 Kyoto, Japan). PCR primers were synthesized by Integrated DNA Technologies (IDT, Coralville, IA,
324 USA). All amplified fragments were purified using the D2000 Gel & PCR clean up kit (D2000-00,
325 Omega Bio-Tek, GA, USA). NEBuilder[®] HiFi DNA Assembly Master Mix kits were purchased from
326 New England Biolabs (E2621S, NEB, Ipswich, MA, USA). All plasmids were extracted using the
327 QIAprep[®] Miniprep kit (27106, QIAGEN, Hilden, Germany). All commercial organic reagents were
328 purchased from Sigma-Aldrich (Louis, MO, USA). Chemically synthesized standards have a purity of
329 at least 95%. Detailed synthesis methods are provided in the Supplementary Information.

330 **Plasmid and strain construction.** Plasmids, strains, and oligonucleotide primers used in this study are
331 listed in **Supplementary Table 2, 3 and 5**, respectively. Fragments used in plasmid construction were
332 amplified by PCR using the corresponding templates and primers and joined using the NEBuilder[®] HiFi
333 DNA Assembly Master Mix kit (**Supplementary Table 4**). Nucleotide and amino acid sequences of
334 enzymes are listed in Supplementary Information (**Supplementary Table 7**). *E. coli* NEB5a used for
335 cloning and plasmid propagation was cultured on selective LA plates (LB with 1.6% agar) or in selective
336 LB medium. Kanamycin, ampicillin, and chloramphenicol were supplemented at 50, 100, and 34 µg
337 mL⁻¹, respectively. All plasmids were verified by digesting with the appropriate restriction enzymes and
338 sequenced. Recombinant *E. coli* BL21(DE3) cells harboring relevant plasmids (**Supplementary Table**
339 **3**) were constructed for product production.

340 **Biosynthetic pathways reconstitution.** To overproduce 4-vinylphenol, styrene, and indole, plasmids
341 containing the corresponding biosynthetic genes were constructed (**Supplementary Table 3**). The *aroF*,
342 *tyrA*, *pheA*, *ppsA*, *tktA*, and *tnaA* genes were amplified from *E. coli* MG1655 genomic DNA. The
343 heterologous genes *paly* from *Rhodotorula toruloides*, *padaA* from *Lactiplantibacillus plantarum*, *pal2*
344 from *Arabidopsis thaliana*, and *fdc1* from *Saccharomyces cerevisiae* were codon-optimized for *E. coli*
345 expression and synthesized by Twist Bioscience. For 4-vinylphenol production, gene fragments *aroF*
346 and *tyrA* under T7 promoter regulation, along with *paly*, *padaA*, *ppsA*, and *tktA* under Trc promoter
347 regulation, were cloned into the pACYC and pET30a(+) vectors using HiFi DNA assembly to generate
348 plasmids pYJ749 and pYJ751, respectively. For styrene production, *aroF* and *pheA* under T7 promoter
349 regulation, together with *pal2*, *fdc1*, *ppsA*, and *tktA* under Trc promoter regulation, were cloned into the
350 pET30a(+) vector to construct plasmid pYJ753. For indole production, the *tnaA* gene fragment was
351 cloned under the control of either the Lac promoter or araBAD promoter into the pACYC vector using
352 HiFi DNA assembly, resulting in plasmids pYJ755 and pYJ783, respectively. The recombinant *E. coli*
353 BL21(DE3) strains were constructed by transforming the respective plasmids.

354 **Shake-flask fermentation.** Plasmids carrying genes encoding the biosynthetic pathways for 4-
355 vinylphenol, styrene, and indole production were transformed into *E. coli* BL21(DE3) competent cells.
356 Single colonies were cultured overnight in 5 mL LB medium with appropriate antibiotics at 37 °C and
357 250 rpm to obtain the seed culture. For shake-flask fermentation, the seed culture was inoculated at 1%
358 (v/v) into 50 mL LB medium with appropriate antibiotics in a 250 mL flask and incubated at 37 °C and
359 220 rpm. When the OD600 reached 0.6-0.8, cells were induced with 0.1 mM IPTG and cultured at 25 °C
360 and 220 rpm. Cell cultures including both the medium and the cell pellets (1 mL) were collected at 24
361 h, 48 h, and 72 h post-induction for analysis. For GC quantification, dodecane (10 mM, 50 µL) was

362 added, and cell cultures were extracted with 1 mL ethyl acetate by vortexing. The product titre was
363 determined using GC based on a calibration curve established with pure standards. Three biological
364 replicates were performed from independent fermentations.

365 **Photobiosynthesis in vials.** Photobiosynthetic strains carrying biosynthetic pathways for substrate and
366 photoenzyme production were constructed by transforming plasmids into *E. coli* BL21(DE3) competent
367 cells. Single colonies were cultured overnight in 5 mL LB medium with appropriate antibiotics at 37 °C
368 and 250 rpm to obtain the seed culture. For initial substrate accumulation under aerobic conditions,
369 shake-flask fermentation was performed by inoculating the seed culture (1%, v/v) into 50 mL LB
370 medium with appropriate antibiotics in a 250 mL flask and incubating at 37 °C and 220 rpm. When the
371 OD₆₀₀ reached 0.6-0.8, cells were induced with 0.1 mM IPTG and cultured at 25 °C and 220 rpm for
372 an additional 48 h. Following fermentation, 20 mL of culture broth was transferred into a 40 mL glass
373 vial (23188, Sigma-Aldrich, Louis, MO, USA) inside a nitrogen-filled glovebox, supplemented with 20
374 g L⁻¹ glucose, 10 mM radical precursors, or 1 mM FMN-Na for complete photobiosynthesis. The culture
375 broth was then placed in a photobiosynthesis setup with stirring and illuminated at 25 °C for 48 h using
376 a Kessil PR160 Rig equipped with a Fan Kit and four 40 W, 440 nm blue LEDs (**Supplementary Fig.**
377 **31**). After illumination, the fermentation broth was extracted with 20 mL ethyl acetate, supplemented
378 with an internal standard-either dodecane (10 mM, 50 µL) for GC-MS quantification or 2-
379 hydroxyindole for HR-LC/MS analysis. The organic extracts were dried over anhydrous MgSO₄,
380 filtered to remove the drying agent, and concentrated. The resulting residue was then resuspended in
381 300 µL of ethyl acetate for GC-MS analysis or 300 µL of methanol for HR-LC/MS determination.

382 **Construction of photoenzyme variants.** For targeted mutagenesis, three PCR fragments were
383 assembled using HiFi assembly. Mutagenesis primers were ordered in 96-deep well plates from IDT.
384 Plasmids serving as PCR templates were linearized with restriction enzymes, purified using a PCR
385 cleanup kit, and stored for further use. The PCR fragments contained 27-40 bp overlapping sequences.
386 The vector backbone PCR was treated with *DpnI* (37 °C for 4 hours, followed by overnight incubation
387 at room temperature), purified, and stored at -20 °C. PCR for forward and reverse fragments was
388 performed separately in 96-well plates, followed by *DpnI* treatment. Q5 DNA polymerase (NEB
389 #M0491) was used for PCR. The HiFi assembly reaction (15 µL) was set up using 30 ng of purified
390 vector backbone PCR, 1.25 µL each of *DpnI*-treated forward and reverse PCR products, and 7.5 µL of
391 HiFi master mix. Homemade competent DH5α cells in a 96-well plate (Bio-Rad #HSS9641) were
392 transformed with 5 µL of the HiFi reaction by heat shock (30 seconds), followed by 1-hour cell growth
393 in 150 µL SOC medium. The resulting cultures were plated on 8-well omnitray plates (120 µL per well)
394 supplemented with kanamycin (50 µg mL⁻¹) and incubated overnight at 37 °C. Colonies were picked
395 and grown overnight at 37 °C in a 96-deep well plate containing 1 mL of Terrific Broth (TB) with
396 kanamycin. Minipreps were performed using the PureLink Pro Quick96 Plasmid Purification Kit
397 (Invitrogen #K211004A), and plasmid DNA from selected mutants was sent for sequencing. The
398 miniprep DNA was then used to transform competent BL21(DE3) cells in a 96-well plate for subsequent
399 whole-cell reactions.

400 For staggered extension process (StEP) recombination⁴⁶, plasmids containing enzyme variants with
401 improved activity (Y82G, T37Q, T37A, W116A, N194A, M39Y, H191S, M39Q, H191Y, Y375E, and
402 Y375L) were combined in equal concentrations to achieve a final DNA mixture concentration of ≥ 60
403 ng µL⁻¹. A master mix (144 µL total) for the first PCR of StEP was prepared as follows: 60 ng µL⁻¹
404 Template (59.98 µL), 1 µM Forward primer (7.2 µL), 1 µM Reverse primer (7.2 µL), 10 mM dNTPs

405 (2.88 μL), 10 \times *Taq* buffer (14.4 μL), 5 U/ μL *Taq* DNA polymerase (2.38 μL), and PCR grade H_2O
406 (49.97 μL). This master mix was aliquoted into six 20 μL reactions, each subjected to different
407 elongation temperatures (50-72 $^\circ\text{C}$) to determine the optimal conditions. Temperature profile for the
408 first PCR in the StEP recombination procedure was set up as follows: Initial denaturation, 95 $^\circ\text{C}$ -5 min;
409 Denaturation, 95 $^\circ\text{C}$ -10 s; Annealing, 55 $^\circ\text{C}$ -1 s; Elongation, 50-72 $^\circ\text{C}$ -1 s; Final elongation, 72 $^\circ\text{C}$ -5
410 min; Hold, 10 $^\circ\text{C}$ - ∞ . The optimal elongation temperature was determined by analyzing the PCR
411 products on an analytical gel, selecting the reaction with the most discrete band. The selected PCR
412 product was treated with 1 μL *DpnI* at 37 $^\circ\text{C}$ for 1 h to digest the parental template. The protocol to
413 amplify 5 μL of the *DpnI* digested reaction mixture with Phusion DNA polymerase was set up as follows
414 (100 μL total): Template (5 μL), 10 μM Forward primer (4 μL), 10 μM Reverse primer (4 μL), DMSO
415 (4 μL), 10 mM dNTPs (2 μL), 5 \times HF buffer (20 μL), 2 U μL^{-1} Phusion DNA polymerase (1 μL), PCR
416 grade H_2O (60 μL). Temperature profile for the second PCR in the StEP recombination procedure was
417 set up as follows: Initial denaturation, 98 $^\circ\text{C}$ -30 s; Denaturation, 98 $^\circ\text{C}$ -10 s; Annealing, 55 $^\circ\text{C}$ -15 s;
418 Elongation, 72 $^\circ\text{C}$ -1 min; Final elongation, 72 $^\circ\text{C}$ -10 min; Hold, 10 $^\circ\text{C}$ - ∞ . The PCR products were
419 analyzed on a 1% agarose gel, purified using a DNA gel recovery kit, and subsequently used for plasmid
420 construction. The amplified and purified DNA fragments were assembled using HiFi DNA assembly
421 with corresponding vector fragments. Homemade electroporation competent *E. coli* BL21(DE3) cells
422 (60 μL) were transformed with 10 μL of the HiFi reaction using 1 mm cuvettes (Bio-RAD) under the
423 following settings: Voltage-1250, Capacity-25, Resistance-100 Ω . Post-transformation, cells were
424 recovered in 1 mL SOC medium and incubated at 37 $^\circ\text{C}$ for 1 h. Transformed cultures were plated on
425 kanamycin (50 $\mu\text{g mL}^{-1}$) LB agar plates and incubated overnight at 37 $^\circ\text{C}$. Colonies were picked and
426 grown overnight at 37 $^\circ\text{C}$ in a 96-deep well plate containing 0.5 mL of LB medium with kanamycin.
427 After incubation, 0.5 mL 40% glycerol was added to each well for storage at -80 $^\circ\text{C}$.

428 **High-throughput whole-cell reactions.** The photobiosynthesis strains in a 96-deep well plate were
429 inoculated into fresh LB medium supplemented with 50 $\mu\text{g mL}^{-1}$ kanamycin in a new 96-deep well plate
430 and incubated overnight at 37 $^\circ\text{C}$ with shaking at 220 rpm. The overnight seed cultures were then
431 inoculated into a 24-deep well plate (1%, v/v) containing 6 mL TB per well with 50 $\mu\text{g/mL}$ kanamycin
432 and grown at 37 $^\circ\text{C}$ with shaking at 200 rpm. Once the OD600 reached 0.4-0.6, the cultures were cooled
433 to 18 $^\circ\text{C}$ with continued shaking (200 rpm) for 30 min. Protein expression was induced by adding IPTG
434 to a final concentration of 0.1 mM, followed by incubation at 18 $^\circ\text{C}$ with shaking at 200 rpm for 18 h.
435 After measuring OD600, approximately 60 OD600 units of each culture were collected by
436 centrifugation at 3,000 g for 10 min, and the supernatants were discarded. The cell pellets (~100 μL per
437 well) were resuspended in 220 μL M9 buffer inside a nitrogen-filled glovebox and transferred to a 96-
438 deep well plate (DWP-7651-S0-C, STELLAR SCIENTIFIC). The following components were added
439 to each well: 4-vinylphenol (100 mM stock in DMSO, 40 μL), indole (100 mM stock in DMSO, 40 μL),
440 glucose (40% stock in H_2O , 50 μL), and FMN-Na (10 mM stock in H_2O , 50 μL). This resulted in the
441 desired final concentrations, with a total reaction volume of 500 μL and a final cell concentration of
442 OD600 = 120. The 96-deep well plate was sealed with a sticky cover, and the reactions were carried
443 out using a Lumidox[®] II 96-Well LED Array equipped with an active cooling base. The plate was
444 shaken at 900 rpm using a Deep Well Plate Thermoshaker (Mfr. No. TS-DW USA) at 25 $^\circ\text{C}$ for 48 h
445 (**Supplementary Fig. 32**). To quench the reaction, 800 μL of ethyl acetate and 40 μL of 2-
446 hydroxyindole (100 mM stock) were added. The plate was then sealed with an organic-resistant mat

447 and shaken overnight at 900 rpm. After centrifugation at 3,000 g for 10 min, approximately 600 μ L of
448 the supernatant was collected, transferred to a new 96-deep well plate, and air-dried in a chemical hood.
449 The resulting residues were then resuspended in 300 μ L methanol. Following another centrifugation at
450 3,000 g for 10 min, 100 μ L of the supernatant was collected and analyzed by LC-MS.

451 **Fed-batch fermentation.** For fed-batch fermentations in bench-top bioreactors (DASbox, Eppendorf,
452 Hamburg, Germany), single colonies of *E. coli* BL21(DE3) strains were inoculated into 5 mL of LB
453 medium supplemented with appropriate antibiotics and cultured overnight at 37 °C with shaking at 250
454 rpm. In the following day, 2 mL of seed culture was transferred into 200 mL of LB medium, or M9
455 minimal medium (Na_2HPO_4 30 g L^{-1} , KH_2PO_4 , 15 g L^{-1} , NaCl 2.5 g L^{-1} , NH_4Cl 5 g L^{-1} , Thiamine-HCl
456 50 mg L^{-1} , Glucose 1 g L^{-1} , 1 M $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$ 2 mL L^{-1} , Trace elements (92949-25ML, Sigma) 1 mL
457 L^{-1} , Amino acid mixture (CSM, 114500012-CF, MP Biomedicals) 0.79 g L^{-1} , Tyrosine 2.5 mM,
458 Tryptophan 2.5 mM), containing a low concentration of glucose (0.5-1 g L^{-1}) in the DASbox bioreactor.
459 The cultures were incubated at 37 °C with an agitation speed of 250 rpm, while the pH was maintained
460 at 6.5 using 4 N HCl and 10 M NaOH. To ensure sufficient oxygen availability, industrial-grade O_2 gas
461 was continuously sparged into the bioreactors, maintaining a dissolved oxygen (DO) level of 30%. To
462 control foaming, a drop of Antifoam 204 was added as needed. After approximately 5 hours of
463 cultivation, when the OD600 reached 2.5-3.5, the temperature was lowered to 25 °C, and IPTG was
464 added to a final concentration of 0.1 mM to induce protein expression. The fermentation continued
465 under aerobic conditions to facilitate substrate accumulation. Once specific fermentation conditions
466 were met, the process transitioned to an anaerobic phase by switching from O_2 to N_2 sparging. The N_2
467 supply was maintained for approximately 10 hours to deplete residual O_2 , ensuring anaerobic conditions.
468 Subsequently, 10 mM radical precursors were added for semi-photobiosynthetic fed-batch fermentation,
469 or 1 mM FMN-Na was added for complete photobiosynthesis, prior to starting the illumination. To
470 initiate photobiosynthesis, the cultures were illuminated with blue light using a Kessil PR160 Rig
471 equipped with four 40 W, 440 nm blue LEDs (**Supplementary Fig. 33**). For fermentations utilizing
472 pure glucose, an additional 50 g L^{-1} of glucose was supplemented into the bioreactors, while the pH was
473 maintained at 6.5 using 4 N HCl and 10 M NaOH. Samples were collected at regular intervals to monitor
474 product formation, glucose and substrate accumulation and consumption, and cell growth. Each fed-
475 batch fermentation was conducted with two or three biological replicates to ensure reproducibility.

476 **Cell viability assays.** To evaluate the viability of *E. coli* BL21(DE3) during prolonged illumination
477 under anaerobic conditions, live/dead staining was performed using the LIVE/DEAD[®] BacLight[™]
478 Bacterial Viability Kit (L7012, Thermo Fisher Scientific, USA). The procedures were modified based
479 on the manufacturer's instructions. Cell samples were collected at defined time points and washed three
480 times with PBS buffer. After the final wash, the cells were resuspended in PBS and diluted to an OD600
481 of approximately 0.2. For measurement, 100 μ L of each cell suspension was transferred into individual
482 wells of a 96-well flat-bottom microplate (in duplicate). To generate a standard curve, live and 70%
483 isopropyl alcohol-killed cell suspensions were mixed in defined ratios (0:100, 10:90, 30:70, 50:50,
484 70:30, 90:10, and 100:0) and similarly distributed into wells. The staining solution was prepared by
485 mixing 6 μ L of Component A and 6 μ L of Component B, followed by dilution with 2.0 mL of sterile
486 deionized water to yield a 2X staining solution. Then, 100 μ L of the 2X stain was added to each well,
487 and the plate was mixed thoroughly by pipetting. After incubation in the dark at room temperature for
488 15 minutes, fluorescence was measured using a microplate reader with excitation at 485 nm, and
489 emission collected at 530 nm (green, live cells) and 630 nm (red, dead cells). Cell viability was analyzed

490 by calculating the fluorescence intensity ratio (F_{530}/F_{630}) of each sample, with reference to the standard
491 curve to determine the percentage of live cells.

$$492 \quad (1) \text{ Ratio} \left(\frac{G}{R} \right) = \frac{F_{cell,em1}}{F_{cell,em2}}$$

493 **GC, GC/MS and HR-LC/MS analyses.** Analysis of 4-vinylphenol, styrene, and indole was performed
494 using an Agilent Technologies GC system equipped with a DB-5ms column (122-5532UI, Agilent).
495 The GC oven temperature was initially maintained at 50 °C for 3 minutes, then ramped to 320 °C at a
496 rate of 20 °C min⁻¹, and held at 320 °C for 1.5 minutes. For GC-MS analysis, an Agilent Technologies
497 GC-MS system equipped with a DB-5ms column was used. The GC oven temperature was programmed
498 to increase from 50 °C to 180 °C at a rate of 20 °C min⁻¹, followed by an increase to 315 °C at a rate of
499 50 °C min⁻¹. A solvent delay of 3 minutes was applied, and single ions of target products were detected.

500 For the enantioselectivity determination of the CPPB product, an Agilent Technologies GC system
501 equipped with a Hydrodex g-TBDAC column (SN 23637-52, Macherey-Nagel) was used. The GC oven
502 temperature was programmed to increase from 50 °C to 220 °C at a rate of 2.5 °C min⁻¹, followed by a
503 30-minute hold at 220 °C.

504 For HR-LC/MS detection, based on our previous study⁴⁹, samples were analyzed using a Q Exactive™
505 Orbitrap mass spectrometer (Thermo Fisher Scientific, USA) coupled with a Vanquish HPLC system
506 (Thermo Fisher Scientific, USA). Chromatographic separation was performed on a Thermo Hypersil
507 GOLD™ aQ column (3 μm, 2.1 × 150 mm; PN 25303-152130). The mobile phases consisted of solvent
508 A (water with 0.1% formic acid) and solvent B (acetonitrile with 0.1% formic acid). A linear gradient
509 elution was applied from 5% to 95% solvent B over 18 minutes, followed by an isocratic hold at 95%
510 B for 5 minutes, at a constant flow rate of 0.2 mL min⁻¹. The autosampler and column compartment
511 were maintained at 4 °C and 25 °C, respectively. Mass spectrometric data were acquired in positive
512 electrospray ionization mode. Full MS scans were performed with the following settings: scan range
513 m/z 50–750, resolution 70,000 FWHM, AGC target 3 × 10⁶, and maximum injection time (IT) of 100 ms.
514 For MS/MS (MS²) acquisition, the instrument was operated at a resolution of 17,500 FWHM, with an
515 AGC target of 1 × 10⁵ and a maximum IT of 50 ms.

516 **Antimicrobial assays.** The antimicrobial activities of the characterized compounds were evaluated
517 against two fungal and 16 bacterial strains, including nine pathogenic strains, using the broth
518 microdilution method same as in our previous study⁴⁹. The indicator strains included *Saccharomyces*
519 *cerevisiae* BY4741, *Issatchenkia orientalis*, *Bacillus halodurans* C-125, *Bacillus subtilis* ATCC 6633,
520 *Lactococcus lactis* CNRZ 481, *Micrococcus luteus* ATCC 4698, *Pseudomonas fluorescens* Pf-5,
521 *Pseudomonas putida* mt-2, *Streptococcus mutans* ATCC 25175, and the following pathogenic bacterial
522 strains: *Acinetobacter baumannii* ATCC 19606, *Bacillus anthracis* str. Sterne, *Bacillus cereus* TZ417,
523 *Enterobacter cloacae*, vancomycin-resistant *Enterococcus faecium* U503 (VRE), *Klebsiella*
524 *pneumoniae* ATCC 27736, *Pseudomonas aeruginosa* PA01, methicillin-resistant *Staphylococcus*
525 *aureus* USA300 (MRSA), and *Staphylococcus epidermidis* 15×154. Fungi were inoculated from
526 glycerol stocks and cultured in 5 mL YPD medium at 30 °C on a rotary shaker (250 rpm). *B. cereus*, *B.*
527 *halodurans*, *B. subtilis*, and *M. luteus* were grown in 5 mL Tryptic Soy Broth (TSB) at 30 °C, while *E.*
528 *cloacae*, *P. fluorescens*, and *P. putida* were cultured in Nutrient Broth (NB) at 30 °C. *L. lactis* was
529 grown in M17 Broth with 0.5% lactose at 30 °C, and the remaining bacterial strains were cultured in
530 Brain Heart Infusion (BHI) medium at 37 °C. Overnight cultures were diluted into fresh sterilized

531 medium and regrown to reach an OD600 of 0.04-0.06. The cells were then diluted 10-fold in fresh
532 medium to achieve a final concentration of approximately 10^6 CFU/mL and distributed into 96-well
533 microtiter plates. The wells were supplemented with test compounds at concentrations ranging from 64
534 to $0.0625 \mu\text{g mL}^{-1}$. The Minimum Inhibitory Concentration (MIC) was determined as the lowest
535 concentration at which no visible growth was observed after 16-18 hours of incubation. All experiments
536 were performed in triplicate, with ampicillin (Amp) and hygromycin (Hyg) included as positive controls
537 for antibacterial assays. For the antimicrobial activity assay against *E. coli*, *E. coli* BL21(DE3) cultures
538 were adjusted to an initial OD600 of 0.5, and 1 mL aliquots were distributed into separate groups. The
539 cell cultures were treated with a series of DIEP concentrations dissolved in DMSO (50, 100, 200, 300,
540 400, 500, 600, 700, 800, and 1000 mg L^{-1}), alongside control groups without compounds or with DMSO
541 alone. After 24 h of treatment, the OD600 of each group was measured. Data were analyzed using
542 GraphPad Prism 8.0.

543

544 **Data availability**

545 The DNA sequences of plasmids used in this study have been provided in the Supplementary
546 Information. The other data are available in the main text, Supplementary Information, Source data, or
547 from the authors upon reasonable request. The SnapGene files for the key plasmids can be accessed at:
548 <https://doi.org/10.5061/dryad.ns1rn8q54>.

549

550 **Acknowledgements**

551 We thank Lucienne Burrus and Teresa Martin for their assistance with the fed batch fermentation
552 experiments. This work was funded by the DOE Center for Advanced Bioenergy and Bioproducts
553 Innovation, under the auspices of the US Department of Energy (DOE), Office of Science, Office of
554 Biological and Environmental Research (award no. DE-SC0018420 to H.Z.). The funders had no role
555 in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

556

557 **Author contributions**

558 The project was coordinated by H.Z., and H.Z., Y.Y. and M.L. jointly conceptualized the project and
559 designed the research experiments. Y.Y., M.L. and H.Z. wrote the manuscript with input from all of the
560 other authors. Y.Y. executed the strains construction, biosynthesis and fed batch fermentation
561 experiments. Y.Y. and M.L. constructed the plasmids. M.L. synthesized the product standards. W.H.
562 contributed to the construction of mutant library. W.H. and Z.Z. were responsible for synthesizing some
563 radical precursors.

564

565 **Competing interests**

566 The authors declare no competing interests.

567

568

569 **References**

- 570 1 Yang, Y. & Arnold, F. H. Navigating the unnatural reaction space: Directed evolution of heme
571 proteins for selective carbene and nitrene transfer. *Acc. Chem. Res.* **54**, 1209-1225 (2021).
- 572 2 Hanefeld, U., Hollmann, F. & Paul, C. E. Biocatalysis making waves in organic chemistry.
573 *Chem. Soc. Rev.* **51**, 594-627 (2022).
- 574 3 Emmanuel, M. A. *et al.* Photobiocatalytic strategies for organic synthesis. *Chem. Rev.* **123**,

575 5459-5520 (2023).

576 4 Buller, R. *et al.* From nature to industry: Harnessing enzymes for biocatalysis. *Science* **382**,
577 eadh8615 (2023).

578 5 Morita, I. & Ward, T. R. Recent advances in the design and optimization of artificial
579 metalloenzymes. *Curr. Opin. Chem. Biol.* **81**, 102508 (2024).

580 6 Kissman, E. N. *et al.* Expanding chemistry through *in vitro* and *in vivo* biocatalysis. *Nature* **631**,
581 37-48 (2024).

582 7 Brouwer, B. *et al.* Noncanonical amino acids: Bringing new-to-nature functionalities to
583 biocatalysis. *Chem. Rev.* **124**, 10877-10923 (2024).

584 8 Birch-Price, Z., Hardy, F. J., Lister, T. M., Kohn, A. R. & Green, A. P. Noncanonical amino
585 acids in biocatalysis. *Chem. Rev.* **124**, 8740-8786 (2024).

586 9 Wu, S. *et al.* Biocatalysis: Enzymatic synthesis for industrial applications. *Angew. Chem. Int.*
587 *Ed.* **60**, 88-119 (2021).

588 10 Peng, Y. *et al.* Recent advances in photobiocatalysis for selective organic synthesis. *Org.*
589 *Process Res. Dev.* **26**, 1900-1913 (2022).

590 11 Yu, J. *et al.* Single-electron oxidation triggered by visible-light-excited enzymes for asymmetric
591 biocatalysis. *Angew. Chem. Int. Ed.* **64**, e202419262 (2025).

592 12 Harrison, W. *et al.* Photobiocatalysis for abiological transformations. *Acc. Chem. Res.* **55**, 1087-
593 1096 (2022).

594 13 Fu, H. & Hyster, T. K. From ground-state to excited-state activation modes: Flavin-dependent
595 "ene"-reductases catalyzed non-natural radical reactions. *Acc. Chem. Res.* **57**, 1446-1457 (2024).

596 14 Jain, S., Ospina, F. & Hammer, S. C. A new age of biocatalysis enabled by generic activation
597 modes. *JACS Au* **4**, 2068-2080 (2024).

598 15 Cheng, L. *et al.* Stereoselective amino acid synthesis by synergistic photoredox-pyridoxal
599 radical biocatalysis. *Science* **381**, 444-451 (2023).

600 16 Wang, T.-C. *et al.* Stereoselective amino acid synthesis by photobiocatalytic oxidative coupling.
601 *Nature* **629**, 98-104 (2024).

602 17 Xu, Y. *et al.* A light-driven enzymatic enantioselective radical acylation. *Nature* **625**, 74-78
603 (2024).

604 18 Xing, Z. *et al.* Synergistic photobiocatalysis for enantioselective triple-radical sorting. *Nature*
605 **637**, 1118-1123 (2025).

606 19 Sun, N. *et al.* Enantioselective [2+2]-cycloadditions with triplet photoenzymes. *Nature* **611**,
607 715-720 (2022).

608 20 Trimble, J. S. *et al.* A designed photoenzyme for enantioselective [2+2] cycloadditions. *Nature*
609 **611**, 709-714 (2022).

610 21 Guo, J. *et al.* Chemogenetic evolution of diversified photoenzymes for enantioselective [2 + 2]
611 cycloadditions in whole cells. *J. Am. Chem. Soc.* **146**, 19030-19041 (2024).

612 22 Tseliou, V. *et al.* Stereospecific radical coupling with a non-natural photodecarboxylase. *Nature*
613 **634**, 848-854 (2024).

614 23 Fu, Y. *et al.* Whole-cell-catalyzed hydrogenation/deuteration of aryl halides with a genetically
615 repurposed photodehalogenase. *Chem* **9**, 1897-1909 (2023).

616 24 Hirschi, S. *et al.* Synthetic biology: Bottom-up assembly of molecular systems. *Chem. Rev.* **122**,
617 16294-16328 (2022).

618 25 Ro, D.-K. *et al.* Production of the antimalarial drug precursor artemisinic acid in engineered

619 yeast. *Nature* **440**, 940-943 (2006).

620 26 Luo, X. *et al.* Complete biosynthesis of cannabinoids and their unnatural analogues in yeast.
621 *Nature* **567**, 123-126 (2019).

622 27 Zhang, J. *et al.* A microbial supply chain for production of the anti-cancer drug vinblastine.
623 *Nature* **609**, 341-347 (2022).

624 28 Gao, J. *et al.* Biosynthesis of catharanthine in engineered *Pichia pastoris*. *Nat. Synth.* **2**, 231-
625 242 (2023).

626 29 Liu, Y. *et al.* Complete biosynthesis of qs-21 in engineered yeast. *Nature*, 1-8 (2024).

627 30 Huang, J. *et al.* Unnatural biosynthesis by an engineered microorganism with heterologously
628 expressed natural enzymes and an artificial metalloenzyme. *Nat. Chem.* **13**, 1186-1191 (2021).

629 31 Huang, J. *et al.* Complete integration of carbene-transfer chemistry into biosynthesis. *Nature*
630 **617**, 403-408 (2023).

631 32 Li, M. *et al.* Asymmetric photoenzymatic incorporation of fluorinated motifs into olefins.
632 *Science* **385**, 416-421 (2024).

633 33 Duan, X. *et al.* Ground-state flavin-dependent enzymes catalyzed enantioselective radical
634 trifluoromethylation. *Nat. Commun.* **16**, 1225 (2025).

635 34 Qi, W. W. *et al.* Functional expression of prokaryotic and eukaryotic genes in *Escherichia coli*
636 for conversion of glucose to p-hydroxystyrene. *Metab. Eng.* **9**, 268-276 (2007).

637 35 Lee, W.-H., Kim, M.-D., Jin, Y.-S. & Seo, J.-H. Engineering of NADPH regenerators in
638 *Escherichia coli* for enhanced biotransformation. *Appl. Microbiol. Biotechnol.* **97**, 2761-2772
639 (2013).

640 36 Ajikumar, P. K. *et al.* Isoprenoid pathway optimization for taxol precursor overproduction in
641 *Escherichia coli*. *Science* **330**, 70-74 (2010).

642 37 McKenna, R. & Nielsen, D. R. Styrene biosynthesis from glucose by engineered *Escherichia*
643 *coli*. *Metab. Eng.* **13**, 544-554 (2011).

644 38 Huang, X. *et al.* Photoenzymatic enantioselective intermolecular radical hydroalkylation.
645 *Nature* **584**, 69-74 (2020).

646 39 Li, M. *et al.* Remote stereocontrol with azaarenes via enzymatic hydrogen atom transfer. *Nat.*
647 *Chem.* **16**, 277-284 (2024).

648 40 Liu, Y. *et al.* Asymmetric synthesis of alpha-chloroamides via photoenzymatic hydroalkylation
649 of olefins. *J. Am. Chem. Soc.* **146**, 7191-7197 (2024).

650 41 Chen, X. *et al.* Photoenzymatic hydrosulfonylation for the stereoselective synthesis of chiral
651 sulfones. *Angew. Chem. Int. Ed.* **62**, e202218140 (2023).

652 42 Harrison, W. *et al.* Photoenzymatic asymmetric hydroamination for chiral alkyl amine synthesis.
653 *J. Am. Chem. Soc.* **146**, 10716-10722 (2024).

654 43 Kumari, A. & Singh, R. K. Medicinal chemistry of indole derivatives: Current to future
655 therapeutic perspectives. *Bioorg. Chem.* **89**, 103021 (2019).

656 44 Zhao, B. *et al.* Direct visible-light-excited flavoproteins for redox-neutral asymmetric radical
657 hydroarylation. *Nat. Catal.* **6**, 996-1004 (2023).

658 45 Lee, J.-H. & Lee, J. Indole as an intercellular signal in microbial communities. *FEMS Microbiol.*
659 *Rev.* **34**, 426-444 (2010).

660 46 Das, A. *et al.* *Methods in enzymology*. Vol. 693, 1-30 (Elsevier, 2023).

661 47 Shimizu, K. & Matsuoka, Y. Feedback regulation and coordination of the main metabolism for
662 bacterial growth and metabolic engineering for amino acid fermentation. *Biotechnol. Adv.* **55**,

663 107887 (2022).
664 48 Trott, O. & Olson, A. J. Autodock vina: Improving the speed and accuracy of docking with a
665 new scoring function, efficient optimization, and multithreading. *J. Comput. Chem.* **31**, 455-
666 461 (2010).
667 49 Yuan, Y. *et al.* Self-resistance-gene-guided, high-throughput automated genome mining of
668 bioactive natural products from *streptomyces*. *Cell Syst.* **16**, 101237 (2025).
669